NCT02421172.

Trial name or title	Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
Methods	This is a phase 2, double‐blind, multicentre RCT with 3 parallel arms
Participants	Participants are men and women 18 to 65 years of age (Hurley stages II to III)
Interventions	CJM112 high dose in period 1; placebo in period 2/placebo in period 1; CJM112 low dose in period 2/placebo in period 1; CJM112 high dose in period 2 CJM112 is a fully human IgG1 monoclonal antibody
Outcomes	Proportion of responders measured by Physician Global Assessment (HS‐PGA) score; timing is not stated
Starting date	April 2015
Contact information	‐
Notes	‐

BD: twice daily.
 DLQI: Dermatology Life Quality Index.
 HISERG: Hidradenitis Suppurativa European Research Group.
 HS: hidradenitis suppurativa.
 HS‐PGA: Hidradenitis Suppurativa Physician's Global Assessment.
 IgG1: immunoglobulin G1.
 Nd:YAG: neodymium‐doped yttrium aluminium garnet.
 PGA: Physician Global Assessment.
 OD: once daily.
 RCT: randomised controlled trial.